Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03180528 · ClinicalTrials.gov registry record · Phase 2
Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer
A Phase 2 study of Skin Basal Cell Carcinoma, sponsored by Kavita Sarin.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03180528 is a Phase 2 study of Skin Basal Cell Carcinoma that has completed, run by Kavita Sarin. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03180528, a Phase 2 study of Skin Basal Cell Carcinoma, has completed, sponsored by Kavita Sarin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase 2 trial studies how well remetinostat works in treating patients with skin basal cell cancer. Remetinostat may slow the growth of basal cell cancer cells.
Conditions Studied
Interventions
- DRUG Remetinostat
Study Locations (1)
California
- Stanford University, School of Medicine - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-07-07 |
| Est. Completion | 2020-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03180528
The ClinicalTrials.gov registry entry for NCT03180528 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kavita Sarin, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Skin Basal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Remetinostat is the first listed.
NCT03180528 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03180528 about?
NCT03180528 is a clinical study titled "Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer". This phase 2 trial studies how well remetinostat works in treating patients with skin basal cell cancer. Remetinostat may slow the growth of basal cell cancer cells.
What is the current status of trial NCT03180528?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2018-07-07. Estimated completion is 2020-12-31.
What conditions does trial NCT03180528 study?
This clinical trial studies the following conditions: Skin Basal Cell Carcinoma.
What interventions are being tested in trial NCT03180528?
The interventions under investigation include: Remetinostat (DRUG).
Who is sponsoring clinical trial NCT03180528?
This trial is sponsored by Kavita Sarin, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03180528 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Basal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Active Surveillance for the Treatment of Low-Risk Basal Cell Carcinoma in Elderly Patients
RECRUITING · NA
-
Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.